Breast cancer survivors who experienced trauma early in life and depression after their cancer treatments are at increased risk of persistent fatigue, a new UCLA study shows. Some of the key predictors of longer-term fatigue for this group of women include elevated levels of depressive symptoms after treatment and a history of childhood adversity, such as abuse, neglect, household conflict and disorganization.
Previous studies have shown that Mexican immigrants living in the United States are less likely to have insurance or to report a usual source of care than Mexican-Americans, other Latinos and non-Latino whites. But the Affordable Care Act may have made it easier for them to access health care when they need it.
Cardiovascular diseases, chronic respiratory diseases and diabetes are among the leading causes of death worldwide. A new UCLA study has found that Bangladesh, Haiti, Malawi, Nepal and Tanzania each has fewer than five health facilities that can provide the full suite of supplies and equipment, trained staff and medication that are needed to properly diagnose and treat all three diseases.
Elective hip and knee replacements may represent a significant source of potentially controllable healthcare spending, according to a March 13 Viewpoint article published in the Journal of the American Medical Association (JAMA) and authored by members of the
IN THE UNITED STATES, ABOUT ONE IN EIGHT women will be diagnosed with breast cancer in their lifetime. The diagnosis does not typically happen at a young age; most commonly, it is the result of acquired mutations in breast tissue over the life course, with the risk of these mutations increasing with age.
UCLA researcher Dr. Roshan Bastani will lead a $6.6 million research study awarded by the Patient-Centered Outcomes Research Institute (PCORI) to investigate the comparative effectiveness of strategies designed to increase receipt of the human papillomavirus (HPV) vaccine among adolescents.
A fundamental shift in how cancer research is conducted and cancer care is provided in the United States is required in order to deliver on the US Cancer Moonshot initiative, according to a major new report published today in The Lancet Oncology.
Of the nearly 4 million women in the United States who have had either breast cancer or ovarian cancer, at least 1.5 million have a high risk of carrying certain types of genetic mutations that could increase their risk for additional cancers in the future.
And although the mutations, including those that affect the BRCA1 and BRCA2 genes, can be identified through a simple blood or saliva test, more than 80 percent of those women have not taken the test or even discussed it with a health care provider, according to a new study from the UCLA Fielding School of Public Health.